Agenda just released for the ISP50: Sensing in Precision Medicine and Digital Health
Posted on 02/03/2020
The ISP50 workshop will bring together relevant communities, sensor technology providers and new molecular characterisation technology developers, as well as innovators, working in digital health & AI, and other relevant stakeholders such as innovation funders.
It aims to facilitate knowledge sharing, stimulate new ideas generation, develop new collaborations, and promote the innovation development and the adaptation of such sensing technologies in the UK health industries.
Leading experts will discuss key subjects relevant to market challenges and opportunities, state of the art sensing technologies, emerging sensing technologies, as well as relevant innovation funding opportunities in the UK.
The event will also have exhibition stands for industrial exhibitors interested in showcasing their technologies, expertise, and capabilities to the event participants.
Agenda (Subject to Change)
09:30 Arrival & Registration
10:00 Welcome, Knowledge Transfer Network
10:05 Introduction to Knowledge Transfer Network
Market Challenges & Opportunities
10:15 Digitising the Future Patient Monitoring System, Practice, Challenges & Opportunities – Jaquie Finn, Cambridge Consultants
10:45 Digital Health Challenges & Needs
11:15 Refreshment Break & Networking
State of Art Commercial Sensing Technologies
11:45 Deep Machine Learning Models for Cancer Detections – Mustafa Alhamdi, Innovative Physics Ltd
12:15 Digital Phenotypic Markets From Wearable Sensors: Depression & Parkinson’s Disease – Charles Nduka, Emteq Ltd
12:45 Bloodlessly Monitoring Serum Analyses Using Non-Invasive Biosensors – Jack Jachmann, Cambridge Medical Technologies
13:15 Lunch & Networking
Enabling Technologies (Sensing, AI & Omics)
14:15 The Tricorder is Dead – Long Live the Tricorder – Keith Errey , Isansys Lifecare Ltd
14:45 Segmental Microfluidic Sensing Technology for Precision Medicine – Xize Niu , SouthWestSensor Ltd
15:15 Implantable Technology for Medical Care – Anna-Louisa Schaffgotsch, Impli Limited
Relevant Funding Opportunities
15:45 Innovate UK & Relevant Funding Opportunities
16:15 Close & Networking
Jaquie Finn is the Global Head of Digital Health at Cambridge Consultants and has worked in genomics, big data, product management and market strategy for over 20 years. Jaquie spends a lot of her time advising and guiding clients on their digital transformation roadmap and strategy as well as helping clients to build out not just smart connected devices but the digital ecosystem and partner network that must wrap around the device in order to be commercially successful.
Jaquie has taken many products and services through from conception to launch that are commercially successful in the market today, including ophthalmic devices, SaaS management tools, genomics platforms and Intelligence analysis software platforms.
Jaquie is a Member of the Chartered Institute of Marketing (CIM) and has worked across many industry verticals such as pharma, ophthalmology, medtech, telecommunications, bioinformatics, intelligence, food and hygiene and life sciences.
Dr. Mustafa Alhamdi considers himself as a data scientist specialist in medical, radiation and sensing industries. He holds a Ph.D degree from the university of Portsmouth. His research interest is toward detecting heart abnormalities from the electrocardiograph (ECG) signals and detecting different types of cancer from the CT scan or MRI images. Variety of publications at IEEE and other journals and conferences documented his heart arrhythmia detection approach. Autoregressive modelling with bank of classifiers such as k-nearest neighbour and support vector machines have been used to achieve 100 % accuracy on the MIT-BIH ECG database.
Recently, Dr. Alhamdi involved in the development of lung cancer detection using convolutional neural network (CNN). Variety of prepossessing methods to denoise and detrend the CT scan images have been used before the training session of VGG and U-net neural network models.
In addition to the medical interest, Dr. Alhamdi recently published work in the field of radiation detection of thermal neutrons using Boron based sensors. Using modern methods of computer vision and 3D modelling to build 3D images for radiation environments has improved the radiation detection capabilities. With previous work experience on mobile telecommunication systems such as GSM and CDMA, Dr. Alhamdi has the knowledge and understanding of variety of security, digital & analogue processing and microwave signals. Dr. Alhamdi uses MATLAB and python as the main programming environments for developing those models. Windows applications and Linux applications using C++ language have been used to simulation radiation environments and CT scan backpropagation models.
Charles Nduka qualified in medicine from both Oxford University and Imperial College and became a consultant plastic surgeon at Queen Victoria Hospital (QVH) in West Sussex, UK in 2005. He is an honorary consultant at Guy’s and St Thomas Hospital, London, and an honorary senior lecturer at Imperial College London and the University of Sussex. He founded the UK’s largest multi-disciplinary facial palsy service at QVH in 2007 with colleagues in physiotherapy, speech and language therapy, maxillo-facial surgery, oculoplastic surgery, and psychological therapy.
In 2012 he co-founded the charity Facial Palsy UK to improve support, research and patient information. He is on the council for the British Association of Aesthetic Plastic Surgeons. Charles maintains an active research interest particularly in the assessment of facial expressions in mental health and around the management of synkinesis.
Passionate about technology to improve lives Charles co-founded the emotion sensing company Emteq Ltd. Embedding patent-pending sensors into augmented reality (AR) glasses and virtual reality (VR) headsets, Emteq is able to accurately infer the emotions of the wearer through continuous monitoring. Combined with artificial intelligence analytics platforms, Emteq are leading the way in developing wearables to help monitor mental ill-health in people with depression, Parkinson’s disease and facial palsy.
Mr. Jack Jachmann attended the City University of New York and Columbia University, and actually began his business career selling computers and other forms of office and hospital equipment on a part time basis while a graduate student. Upon leaving school he joined the Dictaphone Corporation, where he rose through various corporate positions in marketing, product planning, and product development. Jack ultimately become Vice President of R&D and Strategic Planning for Dictaphone, then moved into general management as CEO of two other Pitney Bowes (the parent company of Dictaphone) subsidiary companies.
For Jack the most critical element of enterprise success is product innovation, which he often achieved on a scale that far exceeded the financial and technological resources of the companies he managed. That scale was nevertheless achieved through engineering and manufacturing collaborations with other companies in Europe and Asia, enabling radical product innovation without requiring the degree of internal infrastructure expansion that might normally complement an aggressive innovation strategy. Jack later founded a semiconductor company in California that ultimately listed on the London Stock Exchange and was CEO of a Xerox Corporation subsidiary before being recruited by a private equity group to turn around a chemical company for exit. Jack then commenced work on noninvasive biosensing innovation and founded Cambridge Medical Technologies (CMT) in 2015.
The novel biosensor developed at CMT uses subcutaneous interstitial fluid to detect and monitor a variety of blood biomarkers in real-time and without skin puncture. The sensor has been independently and clinically validated by Harvard University Hospitals and the company is collaborating with several UK universities including Cambridge. CMT has been awarded two Innovate UK grants together with two grants from the National Institutes of Health in the US to further develop the biosensing platform for a range of critical medical applications.
Keith Errey is the CEO and co-founder of Isansys Lifecare Ltd. An entrepreneur with a long practical interest in technology businesses that originate from translational research he has physics degrees from Oxford University and the University of New South Wales, and wide experience in industry and education. He is a strong advocate of digital health and data driven methods in healthcare and a founding member of the Bessemer Society.
Dr. Xize Niu
Dr. Xize Niu is an Associate Professor at the Faculty of Engineering and Physical Sciences, University of Southampton. His research focus is on microfluidics and lab-on-a-chips. His group has pioneered wearable/portable microfluidic sensors for healthcare and environmental applications, especially for real time and continuous monitoring of biomarker variations in body fluids, and nutrients and pollutants in environmental fluids.
In healthcare, this new lab-to-patient approach can provide high frequency and accurate measurement, thereby revealing the trends of biomarker/drug variation, giving insight into patients’ critical conditions or their response to a specific treatment. He has published over 100 peer-reviewed papers with about 3000 citations. Dr. Niu is also the founder and director of SouthWestSensor Limited (SWS), a university spin-out company developing and commercialising these innovative microfluidics sensors.
Anna Luisa Schaffgotsch
Anna Luisa Schaffgotsch attained an MSc from Imperial College in Biotechnology with a particular focus on Synthetic Biology as well as Biophysics. Anna Luisa subsequently gained extensive commercial experience in the life sciences sector.
During her career she was responsible for major portfolios for a chemical trader in London, developed the commercial strategy of a Bioinformatics start up in Germany and was responsible for successfully scaling the European business of an American pharma supply chain company. Her passion for technology within the life sciences industry is reflected by her professional experience, her extensive network in this sector and above all by her decision to build a business to advance and commercialise implantable technologies.
Anna Luisa incorporated Impli Limited in April 2019 with the vision to make people’s lives safer and simpler with implantable technologies. Impli launched its first product in January 2020 with a personal implantable that initially allows its wearer to store medical information onto a user-friendly platform. Anna Luisa and her team at Impli are currently developing further products linking identity and internal biomarkers to enhance precision medicine and preventative healthcare.
Richard joined Hamamatsu in 2007 after studying for a master’s degree in physics at the University of Birmingham. Being able to work in a business environment with the world’s foremost optoelectronic manufacturing organisation, whilst still using knowledge gained during his studies was very attractive.
He has moved through several roles within the organisation over the last 13 years, today heading up the Medical & Analytical Group, responsible for sales and business development activities in these two key application areas for Hamamatsu.